ISO 10993-1:2025 does not automatically require a full rewrite.
For many teams, the real question is where the 2025 logic actually changes the file. Some documents need targeted restructuring. Others need a much deeper rethink because the old logic was already weak before the revision arrived.
A lot of legacy biological evaluation files are now being judged through a 2025 lens. That does not mean every paragraph must be rebuilt. It means teams need to know where the revision really affects reviewer expectations and where the existing file still holds up.
Where the 2025 Revision Usually Changes the File
- Lifecycle framing becomes more visible: the file should feel anchored to the device across its relevant lifecycle, not just to a static testing snapshot.
- Benefit-risk language becomes harder to ignore: weak or generic residual-risk framing now stands out more quickly.
- Test waivers need stronger justification: the standard supports selective testing, but only when the rationale is genuinely argued.
- Chemistry and TRA move closer to the center: they cannot sit like detached appendices when they are essential to the endpoint position.
Where It Often Does Not Require a Full Rewrite
- Device description is still accurate: if the contact profile, materials, and finished-state representation remain sound, that foundation can often stay.
- Evidence base is still relevant: literature, chemistry, legacy testing, or predicate logic may remain usable if they still fit the current device state.
- Endpoint decisions were already reasoned: the file may need clearer language rather than a complete redecision of every endpoint.
What Usually Signals Deeper Rework
- The BER reads like a static literature summary: evidence is listed, but not evaluated as one device-specific biological position.
- The BEP and BER do not tell the same story: planned logic and final conclusions appear disconnected.
- Chemistry exists without consequence: compound lists are present, but they do not influence the endpoint conclusions or risk framing.
- Waived endpoints were never truly defended: the older file may have been accepted internally, but it was never strong enough for current scrutiny.
The Better Way to Scope the Work
- Still defensible: sections that can stay with light reframing.
- Needs targeted upgrade: sections where lifecycle logic, benefit-risk, chemistry integration, or waiver rationale need sharper treatment.
- Needs real reconstruction: sections where the original logic is not directionally usable anymore.
Do not upgrade the whole file at the same intensity. The fastest credible path is to identify where ISO 10993-1:2025 truly changes the argument and fix those sections first.
Key References
- ISO 10993-1:2025 biological evaluation framework
- ISO 14971 linkage where biological evaluation conclusions must fit the risk file
- Legacy BEP and BER upgrade patterns observed in remediation work
- Current reviewer expectations for waiver logic, chemistry integration, and lifecycle framing
Legacy documentation rarely needs equal work everywhere.
A focused review can show whether the real issue is lifecycle framing, benefit-risk language, chemistry integration, or deeper file inconsistency before more rewriting begins.